FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
Larry Pierce, director of cybersecurity and information security officer for Atlantic Health, unpacks how the growth of artificial intelligence is reshaping…
Headline
The Advanced Research Projects Agency for Health Jan. 13 announced a program to develop and implement artificial intelligence tools for…
Headline
Thank you for listening to Advancing Health! As we close out 2025, we’re excited to share highlights from two impactful episodes that sparked dialogue around…
Headline
The Department of Health and Human Services today issued a request for information seeking public comments on how the department can accelerate the…
Headline
The White House Dec. 11 issued an executive order to establish a national artificial intelligence framework to preempt state regulation. The order calls for…
Headline
U.S. and international agencies Dec. 3 released guidance on integrating artificial intelligence into operational technology. The guidance is intended to…